“Individuals with type 2 diabetes and their families seek treatment options that may allow for more individualized care. Awiqli® reduces basal insulin injections from seven to one per week, which may help patients find a basal insulin routine that feels more manageable,” said Michael Radin, MD, executive medical director at Novo. “It is important to continue to discover advanced treatments for the populations that need them today.”
Type 2 diabetes in children and adolescents is a growing public health challenge, as more young people are being diagnosed each year with this chronic disease that requires ongoing care and caregiver support.3 According to a modeling study, it’s anticipated that the number of people ≤19 years old with type 2 diabetes is estimated to reach nearly 84,000 by 2050.4 Healthy nutrition, physical activity, and family support are important aspects of care for type 2 diabetes.2 However, for some young people, these measures may not be enough, potentially leading to complications related to this disease.5 Novo’s approach to pediatric care emphasizes a comprehensive model of support – promoting healthy nutrition, regular physical activity, and diabetes education, alongside proven, age-appropriate treatment options for children and adolescents living with type 2 diabetes.2